Patents by Inventor George Coppola

George Coppola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant ?-galactosidase A therapy for Fabry disease
    Patent number: 7011831
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme ?-galactosidase A. The present invention is directed to recombinant human ?-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of ?-galactosidase A are also provided.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: March 14, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David Hudgins Calhoun, George Coppola
  • Recombinant alpha-galactosidase a therapy for fabry disease
    Publication number: 20040247585
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme &agr;-galactosidase A. The present invention is directed to recombinant human &agr;-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of &agr;-galactosidase A are also provided.
    Type: Application
    Filed: September 4, 2002
    Publication date: December 9, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventors: David Hudgins Calhoun, George Coppola
  • Recombinant &agr;-galactosidase a therapy for Fabry disease
    Patent number: 6461609
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme &agr;-galactosidase A. The present invention is directed to recombinant human &agr;-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of &agr;-galactosidase A are also provided.
    Type: Grant
    Filed: January 29, 1997
    Date of Patent: October 8, 2002
    Assignee: Research Foundation of the City University of New York
    Inventors: David Hudgins Calhoun, George Coppola
  • Recombinant .alpha.-galactosidase A therapy for Fabry disease
    Patent number: 5658567
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 19, 1997
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David Hudgins Calhoun, George Coppola
  • Recombinant .alpha.-galactosidase a therapy for Fabry disease
    Patent number: 5179023
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.
    Type: Grant
    Filed: May 7, 1990
    Date of Patent: January 12, 1993
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David H. Calhoun, George Coppola